CY1120928T1 - Πρωτεϊνες συντηξης για τη θεραπεια διαταραχων του μεταβολισμου - Google Patents
Πρωτεϊνες συντηξης για τη θεραπεια διαταραχων του μεταβολισμουInfo
- Publication number
- CY1120928T1 CY1120928T1 CY181101017T CY181101017T CY1120928T1 CY 1120928 T1 CY1120928 T1 CY 1120928T1 CY 181101017 T CY181101017 T CY 181101017T CY 181101017 T CY181101017 T CY 181101017T CY 1120928 T1 CY1120928 T1 CY 1120928T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fusion proteins
- treatment
- metabolism disorders
- fgf21
- protein
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 3
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Η εφεύρεση σχετίζεται με τον προσδιορισμό των πρωτεϊνών σύντηξης που περιέχουν παραλλαγές πολυπεπτιδίων και πρωτεΐνης του παράγοντα ανάπτυξης ινοβλαστών 21 (FGF21) με βελτιωμένες φαρμακευτικές ιδιότητες. Επίσης παρουσιάζονται μέθοδοι για τη θεραπεία διαταραχών που σχετίζονται με τον FGF21, συμπεριλαμβανομένων των μεταβολικών συνθηκών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161539280P | 2011-09-26 | 2011-09-26 | |
PCT/US2012/057384 WO2013049247A1 (en) | 2011-09-26 | 2012-09-26 | Fusion proteins for treating metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120928T1 true CY1120928T1 (el) | 2019-12-11 |
Family
ID=46970456
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181101017T CY1120928T1 (el) | 2011-09-26 | 2018-10-03 | Πρωτεϊνες συντηξης για τη θεραπεια διαταραχων του μεταβολισμου |
CY20211100868T CY1124697T1 (el) | 2011-09-26 | 2021-10-06 | Πρωτεϊνες συντηξης για τη θεραπεια διαταραχων του μεταβολισμου |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100868T CY1124697T1 (el) | 2011-09-26 | 2021-10-06 | Πρωτεϊνες συντηξης για τη θεραπεια διαταραχων του μεταβολισμου |
Country Status (41)
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169984B (zh) | 2006-07-25 | 2016-08-03 | 利普生技术有限公司 | N末端聚唾液酸化 |
BRPI0809583B1 (pt) | 2007-03-30 | 2022-02-22 | Ambrx, Inc | Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
PE20141727A1 (es) | 2011-07-01 | 2014-11-26 | Ngm Biopharmaceuticals Inc | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
UY34346A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
AU2013243953A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
AU2013370404B2 (en) | 2012-12-27 | 2017-11-02 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015057908A1 (en) | 2013-10-18 | 2015-04-23 | Novartis Ag | Methods of treating diabetes and related disorders |
AU2014342630B2 (en) | 2013-10-28 | 2020-11-05 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
CN106662577B (zh) | 2014-01-24 | 2020-07-21 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
SG11201702757YA (en) * | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
CN114805533A (zh) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
WO2017021893A1 (en) | 2015-08-03 | 2017-02-09 | Novartis Ag | Methods of treating fgf21-associated disorders |
ES2871036T3 (es) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Fgf21變異體 |
CN109844124B (zh) * | 2016-05-20 | 2023-10-03 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
WO2017205517A1 (en) * | 2016-05-25 | 2017-11-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of secretory disorders |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN |
CN107759694B (zh) * | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
CN110087671A (zh) | 2016-12-22 | 2019-08-02 | 赛诺菲 | 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合 |
WO2018166461A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
CN107050429B (zh) * | 2017-04-01 | 2020-12-15 | 杭州生物医药创新研究中心 | 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用 |
KR20200078425A (ko) * | 2017-05-05 | 2020-07-01 | 트레포일 테라퓨틱스, 인크. | 재조합 변형된 섬유아세포 성장 인자 및 이의 치료적 용도 |
CN109836504B (zh) * | 2017-11-24 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
WO2019119673A1 (zh) | 2017-12-19 | 2019-06-27 | 北京吉源生物科技有限公司 | 一种双基因修饰的干细胞及其用途 |
CA3086649A1 (en) * | 2017-12-22 | 2019-06-27 | Novartis Ag | Methods of treating metabolic disorders with fgf21 variants |
CN116098989A (zh) | 2018-02-08 | 2023-05-12 | 广东东阳光药业有限公司 | Fgf21变体、融合蛋白及其应用 |
CN114903978A (zh) | 2018-07-03 | 2022-08-16 | 百时美施贵宝公司 | Fgf-21配制品 |
CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
CN111944055B (zh) | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
CN112386575B (zh) * | 2019-08-19 | 2023-03-21 | 鲁南制药集团股份有限公司 | 一种代谢调节融合蛋白的冻干制剂 |
MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
CA3164941A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
JP6924291B2 (ja) | 2020-01-21 | 2021-08-25 | シャープ株式会社 | 端末装置、方法、および、集積回路 |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
CN113265007B (zh) * | 2021-06-10 | 2022-02-15 | 江南大学 | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 |
CN115286705B (zh) * | 2021-12-30 | 2024-05-10 | 长江大学 | 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用 |
WO2023245543A1 (en) * | 2022-06-23 | 2023-12-28 | Ampsource Biopharma Shanghai Inc. | Uses of fgf21 fusion proteins |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
JP2003535037A (ja) | 1999-12-23 | 2003-11-25 | ザイモジェネティクス,インコーポレイティド | 炎症を治療する方法 |
US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
WO2005061712A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
SI1751184T1 (sl) * | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fuzijski proteini |
DK1789442T3 (da) * | 2004-09-02 | 2009-11-16 | Lilly Co Eli | Muteiner af fibroblastvækstfaktor 21 |
WO2006078463A2 (en) | 2005-01-21 | 2006-07-27 | Eli Lilly And Company | Method for treating cardiovascular disease |
JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
MX342677B (es) | 2008-10-24 | 2016-10-07 | Novartis Ag * | Pirrolin-carboxi-lisina biosintéticamente generada y modificaciones de proteínas específicas del sitio por medio de la derivación química de residuos de pirrolin-carboxi-lisina y pirrolisina. |
PE20120358A1 (es) * | 2009-05-05 | 2012-04-26 | Amgen Inc | Mutantes fgf21 y usos de los mismos |
CA2760674A1 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
AU2010262927A1 (en) * | 2009-06-17 | 2012-01-19 | Amgen Inc. | Chimeric FGF19 polypeptides and uses thereof |
EP2516458A1 (en) | 2009-12-22 | 2012-10-31 | Novartis AG | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
DE102010038140B4 (de) * | 2010-10-13 | 2020-06-18 | Hettich-Heinze Gmbh & Co. Kg | Beschlag für eine Schiebetür |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
UY34346A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
-
2012
- 2012-09-25 UY UY34346A patent/UY34346A/es active IP Right Grant
- 2012-09-25 US US13/626,194 patent/US9006400B2/en active Active
- 2012-09-25 TW TW101135183A patent/TWI593708B/zh active
- 2012-09-25 JO JOP/2012/0279A patent/JO3476B1/ar active
- 2012-09-26 BR BR112014007069-5A patent/BR112014007069B1/pt active IP Right Grant
- 2012-09-26 AR ARP120103553 patent/AR088044A1/es active IP Right Grant
- 2012-09-26 EP EP17201957.2A patent/EP3321276B1/en active Active
- 2012-09-26 PL PL12768999T patent/PL2760475T3/pl unknown
- 2012-09-26 SG SG10201602339XA patent/SG10201602339XA/en unknown
- 2012-09-26 SG SG11201400538QA patent/SG11201400538QA/en unknown
- 2012-09-26 PE PE2018001106A patent/PE20181159A1/es unknown
- 2012-09-26 HU HUE12768999A patent/HUE039857T2/hu unknown
- 2012-09-26 JP JP2014532117A patent/JP6186361B2/ja active Active
- 2012-09-26 AP AP2014007543A patent/AP2014007543A0/xx unknown
- 2012-09-26 PL PL17201957T patent/PL3321276T3/pl unknown
- 2012-09-26 ES ES17201957T patent/ES2895080T3/es active Active
- 2012-09-26 MX MX2014003677A patent/MX350273B/es active IP Right Grant
- 2012-09-26 RS RS20211120A patent/RS62341B1/sr unknown
- 2012-09-26 AU AU2012316052A patent/AU2012316052A1/en not_active Abandoned
- 2012-09-26 LT LTEP17201957.2T patent/LT3321276T/lt unknown
- 2012-09-26 SI SI201231952T patent/SI3321276T1/sl unknown
- 2012-09-26 PT PT17201957T patent/PT3321276T/pt unknown
- 2012-09-26 SI SI201231391T patent/SI2760475T1/sl unknown
- 2012-09-26 UA UAA201402419A patent/UA113856C2/uk unknown
- 2012-09-26 WO PCT/US2012/057384 patent/WO2013049247A1/en active Application Filing
- 2012-09-26 DK DK12768999.0T patent/DK2760475T3/en active
- 2012-09-26 ES ES12768999.0T patent/ES2689762T3/es active Active
- 2012-09-26 CA CA2849464A patent/CA2849464C/en active Active
- 2012-09-26 EP EP12768999.0A patent/EP2760475B1/en active Active
- 2012-09-26 KR KR1020147010946A patent/KR102085605B1/ko active IP Right Grant
- 2012-09-26 IN IN2043DEN2014 patent/IN2014DN02043A/en unknown
- 2012-09-26 CN CN201710255835.5A patent/CN107266579B/zh active Active
- 2012-09-26 HU HUE17201957A patent/HUE055584T2/hu unknown
- 2012-09-26 PT PT12768999T patent/PT2760475T/pt unknown
- 2012-09-26 CN CN201280057789.3A patent/CN103945871B/zh active Active
- 2012-09-26 MY MYPI2014700650A patent/MY166059A/en unknown
- 2012-09-26 RS RS20181146A patent/RS57868B1/sr unknown
- 2012-09-26 DK DK17201957.2T patent/DK3321276T3/da active
- 2012-09-26 PE PE2014000418A patent/PE20141551A1/es active IP Right Grant
- 2012-09-26 CU CUP2015000171A patent/CU24314B1/xx unknown
- 2012-09-26 HR HRP20211575TT patent/HRP20211575T1/hr unknown
- 2012-09-26 LT LTEP12768999.0T patent/LT2760475T/lt unknown
- 2012-09-26 EA EA201490695A patent/EA039633B1/ru unknown
-
2014
- 2014-03-07 ZA ZA2014/01700A patent/ZA201401700B/en unknown
- 2014-03-12 TN TNP2014000109A patent/TN2014000109A1/en unknown
- 2014-03-13 MA MA36824A patent/MA35437B1/fr unknown
- 2014-03-13 IL IL231533A patent/IL231533B/en active IP Right Grant
- 2014-03-25 CL CL2014000736A patent/CL2014000736A1/es unknown
- 2014-03-26 CO CO14064516A patent/CO6920257A2/es unknown
- 2014-03-26 CR CR20140140A patent/CR20140140A/es unknown
- 2014-03-26 CU CUP2014000034A patent/CU24206B1/es active IP Right Grant
- 2014-03-26 GT GT201400055A patent/GT201400055A/es unknown
- 2014-09-30 HK HK18110595.8A patent/HK1251238A1/zh unknown
-
2015
- 2015-02-24 US US14/630,206 patent/US9266935B2/en active Active
-
2016
- 2016-01-04 US US14/987,338 patent/US10076554B2/en active Active
- 2016-09-02 CL CL2016002215A patent/CL2016002215A1/es unknown
-
2017
- 2017-07-28 JP JP2017146984A patent/JP6567613B2/ja active Active
-
2018
- 2018-08-30 US US16/117,960 patent/US11129874B2/en active Active
- 2018-09-28 HR HRP20181558TT patent/HRP20181558T1/hr unknown
- 2018-10-03 CY CY181101017T patent/CY1120928T1/el unknown
-
2019
- 2019-07-31 JP JP2019141242A patent/JP2020007314A/ja not_active Withdrawn
-
2021
- 2021-03-08 UY UY0001039119A patent/UY39119A/es not_active Application Discontinuation
- 2021-08-24 US US17/410,307 patent/US11944664B2/en active Active
- 2021-10-06 CY CY20211100868T patent/CY1124697T1/el unknown
- 2021-10-25 AR ARP210102949A patent/AR123908A2/es unknown
-
2022
- 2022-01-11 JP JP2022002030A patent/JP7339372B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120928T1 (el) | Πρωτεϊνες συντηξης για τη θεραπεια διαταραχων του μεταβολισμου | |
CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
EA201490697A1 (ru) | Белки с двойной функцией для лечения метаболических расстройств | |
CY1121318T1 (el) | Συμπλοκα λιποπρωτεϊνων και παρασκευη και χρησεις αυτων | |
EA201492053A1 (ru) | Белки фактора роста фибробластов 21 | |
EA202090338A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
CY1121368T1 (el) | Αντισωματα anti-asic1 και χρησεις αυτων | |
EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
EA201491726A1 (ru) | Конъюгаты бороновых кислот олигонуклеотидных аналогов | |
EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
CO7131377A2 (es) | Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos | |
CY1124859T1 (el) | Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων | |
TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders |